ELI LILLY & Co
LLYAPI behind this page
LLY Q1 2026 request
Playground key active
/api/financials?ticker=LLY&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 19,799 | 12,729 | +55.5% |
Show Product Lines breakouts |
|||
| Cardiometabolic Health | 15,760 | 9,208 | +71.2% |
| Cardiometabolic Health · Non Us | 5,836 | 2,631 | +121.8% |
| Cardiometabolic Health · US | 9,924 | 6,577 | +50.9% |
| Collaboration and Other Revenue [Member] | 1,346 | 1,127 | +19.4% |
| Immunology | 1,203 | 1,088 | +10.6% |
| Immunology · Non Us | 584 | 510 | +14.5% |
| Immunology · US | 619 | 578 | +7.1% |
| Jardiance | 1,114 | 1,014 | +9.9% |
| Jardiance · Milestone Payments, Sales-based | 250 | 370 | -32.4% |
| Jardiance · Non Us | 602 | 705 | -14.6% |
| Jardiance · US | 512 | 310 | +65.2% |
| Mounjaro | 8,662 | 3,842 | +125.5% |
| Mounjaro · Non Us | 4,430 | 1,186 | +273.5% |
| Mounjaro · US | 4,232 | 2,656 | +59.3% |
| Neuroscience | 382 | 272 | +40.4% |
| Neuroscience · Non Us | 89 | 83 | +7.2% |
| Neuroscience · US | 293 | 189 | +55.0% |
| Oncology | 2,268 | 1,948 | +16.4% |
| Oncology · Non Us | 1,040 | 902 | +15.3% |
| Oncology · US | 1,228 | 1,046 | +17.4% |
| Other cardiometabolic health | 905 | 945 | -4.2% |
| Other cardiometabolic health · Non Us | 460 | 410 | +12.2% |
| Other cardiometabolic health · US | 446 | 535 | -16.6% |
| Other immunology | 470 | 326 | +44.2% |
| Other immunology · Non Us | 269 | 225 | +19.6% |
| Other immunology · US | 202 | 102 | +98.0% |
| Other oncology | 966 | 789 | +22.4% |
| Other oncology · Non Us | 444 | 400 | +11.0% |
| Other oncology · US | 522 | 388 | +34.5% |
| Product | 18,453 | 11,601 | +59.1% |
| Product And Service Other | 187 | 213 | -12.2% |
| Product And Service Other · Non Us | 130 | 113 | +15.0% |
| Product And Service Other · US | 56 | 100 | -44.0% |
| Taltz | 733 | 762 | -3.8% |
| Taltz · Non Us | 315 | 285 | +10.5% |
| Taltz · US | 417 | 477 | -12.6% |
| Trulicity | 919 | 1,095 | -16.1% |
| Trulicity · Non Us | 318 | 325 | -2.2% |
| Trulicity · US | 600 | 771 | -22.2% |
| Verzenio | 1,302 | 1,159 | +12.3% |
| Verzenio · Non Us | 596 | 501 | +19.0% |
| Verzenio · US | 706 | 658 | +7.3% |
| Zepbound | 4,160 | 2,312 | +79.9% |
| Zepbound · Non Us | 26 | 7 | +271.4% |
| Zepbound · US | 4,134 | 2,305 | +79.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 19,799 | 12,729 | +55.5% |
Show Geography breakouts |
|||
| CN | 693 | 451 | +53.7% |
| Europe | 3,646 | 2,389 | +52.6% |
| JP | 571 | 402 | +42.0% |
| Non Us | 7,680 | 4,239 | +81.2% |
| Rest of world | 2,771 | 997 | +177.9% |
| US | 12,119 | 8,489 | +42.8% |
| Cost of Revenue | 3,577 | 2,225 | +60.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 3,577 | 2,225 | +60.8% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,510 | 2,734 | +28.4% |
Show Product Lines breakouts |
|||
| Early-stage · Reportable Segment | 1,266 | 990 | +27.9% |
| Late-stage · Reportable Segment | 2,244 | 1,744 | +28.7% |
| Selling, General & Administrative | 2,934 | 2,468 | +18.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,934 | 2,468 | +18.9% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 584 | 1,572 | -62.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 584 | 1,572 | -62.8% |
| Restructuring Settlement And Impairment Provisions | 279 | 35 | +697.1% |
| Non-Operating Income (Expense) | 65 | 239 | -72.8% |
| Cost Of Sales Operating Expenses And Other Net | 10,949 | 9,273 | +18.1% |
| Income Before Taxes | 8,850 | 3,456 | +156.1% |
| Income Tax Expense (Benefit) | 1,454 | 697 | +108.6% |
| Net Income | 7,396 | 2,759 | +168.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 7,396 | 2,759 | +168.1% |
| EPS (Basic) | 8.27 | 3.07 | +169.4% |
| EPS (Diluted) | 8.26 | 3.06 | +169.9% |
| Wtd Avg Shares (Basic) | 894.5 | 898.7 | -0.5% |
| Wtd Avg Shares (Diluted) | 895.9 | 900.6 | -0.5% |
| Interest Expense (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 332 | 244 | +36.1% |
| Net Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | 7,396 | 2,759 | +168.1% |
| Comprehensive Income | 7,443 | 3,306 | +125.1% |
| Other Comprehensive Income | 47 | 547 | -91.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 47 | 547 | -91.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,282 | 3,093.3 | +70.8% |
| Accounts Receivable | 18,429 | 12,036.6 | +53.1% |
| Other Receivables Net Current | 2,748 | 1,966.6 | +39.7% |
| Inventory | 14,529 | 9,311 | +56.0% |
| Prepaid Expense Current | 13,633 | 14,653.9 | -7.0% |
| Other Assets Current | 214 | 72.4 | +195.6% |
| Total Current Assets | 54,835 | 41,261.2 | +32.9% |
| Non-Current Assets | |||
| Long Term Investments | 3,116 | 3,222.7 | -3.3% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 3,116 | 3,222.7 | -3.3% |
| Goodwill | 6,130 | 5,770.5 | +6.2% |
| Intangible Assets Net Excluding Goodwill | 7,374 | 6,012.2 | +22.7% |
| Deferred Tax Assets | 11,350 | 8,573.2 | +32.4% |
| Property, Plant & Equipment | 26,540 | 18,474.1 | +43.7% |
| Other Non-Current Assets | 7,231 | 6,074.9 | +19.0% |
| Total Assets | 116,576 | — | — |
| Current Liabilities | |||
| Debt Current | 4,000 | 4,016.4 | -0.4% |
| Accounts Payable | 5,029 | 3,442 | +46.1% |
| Employee Related Liabilities Current | 1,359 | 1,113.9 | +22.0% |
| Sales Rebates And Discounts | 17,547 | 11,550.3 | +51.9% |
| Other Liabilities Current | 8,699 | 3,769.8 | +130.8% |
| Total Current Liabilities | 36,634 | 30,068.1 | +21.8% |
| Commercial Paper (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Carrying Reported Amount Fair Value Disclosure | 1,775 | — | — |
| Fair Value Inputs Level2 · Estimate Of Fair Value Fair Value Disclosure | 1,771 | 2,481.9 | -28.6% |
| Non-Current Liabilities | |||
| Long-Term Debt | 39,370 | 34,499.5 | +14.1% |
| Accrued Income Taxes Noncurrent | 5,289 | 5,370.5 | -1.5% |
| Other Non-Current Liabilities | 4,085 | 2,288.4 | +78.5% |
| Liabilities Noncurrent | 48,744 | 43,473.9 | +12.1% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Carrying Reported Amount Fair Value Disclosure | 41,595 | — | — |
| Fair Value Inputs Level2 · Estimate Of Fair Value Fair Value Disclosure | 38,233 | — | — |
| Stockholders' Equity | |||
| Common Stock | 590 | 592.6 | -0.4% |
| Additional Paid In Capital Common Stock | 6,921 | 6,910 | +0.2% |
| Retained Earnings | 29,514 | 15,099.5 | +95.5% |
| Common Stock Shares Held In Employee Trust | -3,013 | -3,013.2 | 0.0% |
| Accumulated Other Comprehensive Income | -2,833 | -3,774.6 | +24.9% |
| Other Additional Capital | 19 | — | — |
| Total Stockholders' Equity | 31,198 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1,989 | -2,182 | +8.8% |
| Accumulated Other Comprehensive Income | -2,833 | -3,775 | +25.0% |
| Accumulated Translation Adjustment | -1,099 | -1,824 | +39.7% |
| Additional Paid In Capital | 6,921 | 6,910 | +0.2% |
| Common Stock | 590 | 593 | -0.5% |
| Other | 254 | 230 | +10.4% |
| Retained Earnings | 29,514 | 15,100 | +95.5% |
| Total Liabilities & Equity | 116,576 | 89,388.8 | +30.4% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 509 | 463 | +9.9% |
| Increase Decrease In Deferred Income Taxes | -1,478 | -392 | -277.0% |
| Stock-Based Compensation | 161 | 154 | +4.5% |
| Increase Decrease In Other Operating Capital Net | -1,664 | -3,364 | +50.5% |
| Other Operating Activities Cash Flow Statement | -175 | 474 | -136.9% |
| Net Cash from Operations | 5,333 | 1,666 | +220.1% |
| Investing Activities | |||
| Payments To Acquire Other Property Plant And Equipment | -2,326 | -1,510 | -54.0% |
| Payments To Acquire Other Investments | -297 | -197 | -50.8% |
| Payments To Acquire In Process Research And Development | -204 | -1,757 | +88.4% |
| Other Payments To Acquire Businesses | -1,058 | — | — |
| Other Investing Activities | -31 | 111 | -127.9% |
| Net Cash from Investing | -3,916 | -3,353 | -16.8% |
| Financing Activities | |||
| Payments Of Dividends | -1,548 | -1,346 | -15.0% |
| Proceeds From Repayments Of Short Term Debt | 1,775 | -1,849 | +196.0% |
| Repayments Of Long Term Debt | -750 | — | — |
| Share Repurchases | -2,356 | -1,200 | -96.3% |
| Proceeds From Payments For Other Financing Activities | -591 | -686 | +13.8% |
| Net Cash from Financing | -3,470 | 1,380 | -351.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 67 | 132 | -49.2% |
| Net Change in Cash | -1,986 | -175 | -1034.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 5,282 | 3,093 | +70.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.